Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd experienced a significant gap down at market open on 09 Mar 2026, reflecting heightened market concerns and a weak start to the trading day. The stock opened sharply lower by 15.18%, underperforming its sector and broader indices amid persistent volatility and negative technical signals.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd experienced a significant gap down at market open today, reflecting heightened market apprehension. The stock opened 7.47% lower, continuing a six-day losing streak amid persistent volatility and sector-wide pressures.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with the latest insights into its performance and outlook.

Gujarat Themis Biosyn Ltd (stock code 925632) has experienced a notable shift in its technical parameters, moving from a mildly bearish to a bearish trend. Despite a modest day gain of 2.38%, the company’s technical indicators, including MACD, RSI, and moving averages, signal caution for investors amid a challenging market backdrop and a Mojo Grade downgrade from Hold to Sell.

Gujarat Themis Biosyn Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting a complex interplay of bearish and bullish signals. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price momentum and technical indicators present a nuanced picture that investors must carefully analyse.

Gujarat Themis Biosyn Ltd recorded a robust intraday performance on 18 Feb 2026, surging to a day’s high of Rs 337.9, marking a 6.81% rise during trading. The stock closed with a notable gain of 7.79%, significantly outperforming its Pharmaceuticals & Biotechnology sector peers and the broader market indices.

Gujarat Themis Biosyn Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with several indicators signalling a bearish trend. Despite a modest day change of 0.11% to close at ₹320.10, the stock’s technical parameters have deteriorated, prompting a downgrade in its Mojo Grade from Hold to Sell as of 21 Jan 2026. This article analyses the recent technical developments, momentum indicators, and the stock’s performance relative to the broader market.

Gujarat Themis Biosyn Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s near to medium-term outlook.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 13 February 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a sideways trend to a mildly bearish stance. The stock’s recent price action, combined with deteriorating technical parameters, suggests caution for investors amid a challenging market environment.

Gujarat Themis Biosyn Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish indicators. Despite a 2.51% gain on 10 Feb 2026, the company’s overall technical and fundamental outlook remains cautious, with a recent downgrade from Hold to Sell by MarketsMOJO signalling tempered investor sentiment.

Gujarat Themis Biosyn Ltd., a speciality pharmaceutical manufacturer, reported net profit of ₹12.46 crores for Q3 FY26 (October-December 2025), marking a 12.63% decline quarter-on-quarter but a 3.93% decline year-on-year. With a market capitalisation of ₹3,609 crores, the small-cap pharma company faces mounting concerns over profitability sustainability despite achieving its highest quarterly revenue run-rate. The stock has declined 1.77% following the results disclosure, currently trading at ₹328.00 and reflecting broader investor unease about the company's ability to justify its premium 74x price-to-earnings multiple.

Gujarat Themis Biosyn Ltd commenced trading on 3 Feb 2026 with a significant gap up, opening 10.55% higher than its previous close, signalling a robust start amid positive market sentiment in the Pharmaceuticals & Biotechnology sector.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.